Wistar Scientists Move HIV Vaccine Research Forward by Developing an Immunogen that Produces Tier-2 Antibodies—the Kind That Matter for Combatting HIV
Wistar Institute scientists take a promising step in the direction of developing an HIV vaccine that uses a unique native-like trimer to develop Tier-2 neutralizing antibodies—the kind that matter for combatting HIV—in mice for the first time.
3-Feb-2022 3:55 PM EST Add to Favorites
Novel Nanoparticle SARS-CoV-2 Vaccine Combines Immune Focusing and Self-assembling Nanoparticles to Elicit More Potent Protection
The first generation of COVID-19 vaccines have been highly effective, but also have limitations. Now Wistar scientists have developed a more targeted vaccine that, in animal studies, shows stronger, broader, and more durable protection in a single,...
1-Feb-2022 11:35 AM EST Add to Favorites
A new study by Wistar researchers has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).
17-Jan-2022 5:00 AM EST Add to Favorites
The Wistar Institute and Stanford Medicine to Begin Phase 2 Clinical Trial of VK-2019 in Patients with Epstein-Barr Virus (EBV)-Positive Advanced Nasopharyngeal Carcinoma
Wistar announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.
5-Jan-2022 9:35 AM EST Add to Favorites
Fox Chase Cancer Center, The Wistar Institute Announce Opening of Phase 1 Clinical Trial of Anticancer Drug Candidate
Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer.
2-Dec-2021 11:20 AM EST Add to Favorites
Scientists at The Wistar Institute have identified two genes that play a critical role in protecting ovarian cancer from the immune system.
29-Nov-2021 6:00 PM EST Add to Favorites
The Wistar Institute Receives $4 Million in Funding From the Commonwealth of Pennsylvania to Advance COVID-19 Research, Address COVID-19 Risk on Vulnerable Populations, and Assess Pandemic Preparedness
The Commonwealth of Pennsylvania has granted The Wistar Institute $4 million to fund COVID-19 research focused on understanding the impact of COVID-19 on certain at-risk populations and supporting the commonwealth’s preparation and emergency...
23-Nov-2021 8:50 AM EST Add to Favorites
Wistar Scientists Discover Sugar Molecule on HIV-infected Cell Plays Role in Evading Immune System — They Exploit as Weakness to Make More Effective “Natural Killers” Against HIV
A new Wistar Institute study shows how key features on the surface of HIV-infected cells help the disease evade detection by the immune system.
11-Nov-2021 1:05 PM EST Add to Favorites
See All News
Dr. Luis Montaner, Wistar Institute HIV/AIDS Expert, Can Address His Work in the Search for a Cure, for World AIDS Day
26-Nov-2013 2:25 PM EST
22-Feb-2013 4:15 PM EST
The Winter Sun May Not Be Warm, but Still Can Be Dangerous. Wistar Melanoma Expert on Wintertime UV Risks
22-Jan-2013 2:30 PM ESTSee All Experts